linjc16/ctgov huggingface dataset:
Advanced Characterization of Autosomal Dominant Optic Atrophy

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the anatomy of the retina and the optic nerve in patients with autosomal dominant optic atrophy (ADOA). Based on these findings the aim of the study is to determine why patients with the same type of genetic material, i.e. the same mutation, have such large variations of symptoms, spanning from unaffected subjects to blindness. The project requires examination of both healthy and affected family members.

Official Title
-----------------
Cross Sectional Study of Autosomal Dominant Opticus Atrophy

Conditions
-----------------
Optic Atrophy, Autosomal Dominant

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects diagnosed with autosomal dominant optic atrophy Exclusion Criteria: Age below 8 years old

Ages Eligible for Study
-----------------
Minimum Age: 8 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| ADOA<br>This group includes subjects diagnosed with autosomal dominant optic atrophy | |
| Healthy subjects<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| visual acuity |  | 1 day | 
| vessel caliber |  | 1 day | 
| OCT |  | 1 day | 
| Microperimetry |  | 1 day | 
| Lifestyle questionnaire |  | 1 day | 
| General checkup |  | 1 day |
Collagen Alterations in Patients With Abdominal Wall Hernias

Study Overview
=================
Brief Summary
-----------------
The aim of this study was to evaluate collagen turnover in patients with multiple hernias

Detailed Description
-----------------
Venous blood was collected and markers for type IV and V collagen synthesis and breakdown was measured

Official Title
-----------------
Collagen Alterations in Patients With Abdominal Wall Hernias

Conditions
-----------------
Hernia, Abdominal

Intervention / Treatment
-----------------
* Other: Collagen turnover


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with a history of three hernia repairs (multiple hernia group) patients without any history or presence of hernias (control group) Exclusion Criteria: connective tissue disorder (Ehlers-Danloss/Marfan) presence of hernia upon clinical examination (control group)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Multiple hernia group<br>Males undergoing at least three repairs of abdominal wall hernias at three different anatomic locations. Collagen turnover is analysed. | Other: Collagen turnover<br>* Type IV and V collagen synthesis and breakdown<br>|
| Control group<br>Males without any history or presence of hernias | Other: Collagen turnover<br>* Type IV and V collagen synthesis and breakdown<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Type IV and V collagen synthesis and breakdown | Products from type IV and V collagen synthesis and breakdown are measured in serum. with ELISA from Nordic Bioscience A/S, Herlev, Denmark. Specifically, the biomarker for type IV collagen synthesis (P4NP) and breakdown (C4M), and for type V collagen synthesis (P5CP) and breakdown (C5M) was measured. The concentration unit for all parameters is ng/ml. | 3 months |
China Collaborative Study on Epidemiology of Acute Kidney Injury

Study Overview
=================
Brief Summary
-----------------
Acute kidney injury (AKI) is a common clinical syndrome, especially patients in the hospital. AKI has become a huge medical burden in China. Little information is available about this disease burden in our country. The investigators aimed to evaluate the burden of AKI and to analyze the related risk factors.

Detailed Description
-----------------
The investigators launch a nationwide of all patients, who were admitted to hospital from 2011-2016. Patients were diagnosed on the basis of changes in serum creatinine by the laboratory information system. The investigators assessed rates of AKI according to the criteria of 2012 Kidney Disease Improving Global Outcomes (KDIGO).

Official Title
-----------------
China Collaborative Study on Epidemiology of Acute Kidney Injury

Conditions
-----------------
Acute Kidney Injury

Intervention / Treatment
-----------------
* Other: no intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The patients diagnosed on the basis of changes in serum creatinine according to the criteria of 2012 Kidney Disease Improving Global Outcomes(KDIGO) Exclusion Criteria: Serum creatinine record less than two times during hospitalization Patients being diagnosed with End-stage kidney disease (chronic kidney disease stage 5) Nephrectomy Kidney transplantation Peak serum creatinine of less than 53µ mol/L Serum creatinine decrease after amputation
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| AKI<br> | Other: no intervention<br> <br> |
| non-AKI<br> | Other: no intervention<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of AKI |  | Jan. 2011 to Oct. 2016 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Recognition rate of AKI | Using machine learning and deep learning methods to establish AKI prediction model and risk models | Jan. 2011 to Oct. 2016 | 
| Proportion of nephrology referral |  | Jan. 2011 to Oct. 2016 | 
| In-hospital mortality |  | Jan. 2011 to Oct. 2016 | 
| Longer ICU stay |  | Jan. 2011 to Oct. 2016 | 
| Higher medical cost |  | Jan. 2011 to Oct. 2016 |
Evaluation of Complications in Airway Management

Study Overview
=================
Brief Summary
-----------------
In the current study researchers aim to evaluate the rate of the complication due to airway management (during intubation or placement of supraglottic airway devices)

Detailed Description
-----------------
Airway management is one of the most important subject of anesthesia practice. Airway devices ,helping anesthesiologists to maintain airway safety have many complications. 4 th national audit project (NAP 4) study was designed to evaluate the incidence of the major complication of airway management. Accordingly in current study authors aim to determine the complications and incidence of the complications during airway management.

Official Title
-----------------
Evaluation of Complications During Airway Management: An Observational Prospective Cohort Study

Conditions
-----------------
Airway Complication of Anesthesia, Difficult Intubation

Intervention / Treatment
-----------------
* Procedure: airway management


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients undergoing general anesthesia Patients to whom airway devices will be inserted Exclusion Criteria: Patients who undergo surgery under regional anesthesia Patients who undergo surgery under sedation
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| general anesthesia<br>Patients who undergo general anesthesia and are intubated or inserted airway device will be enrolled. researchers will follow the induction and intubation period and record all the complications due to airway management. | Procedure: airway management<br>* patients will be intubated or will be placed an airway device<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The incidence of the complications due to airway management | researchers will observe the whole patients who undergo general anesthesia and record the data | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| variety of complications and reasons of the complications | researchers will observe the whole patients who undergo general anesthesia and record the data | 6 months | 
| preventable reasons of the complications | researchers will observe the whole patients who undergo general anesthesia and record the data | 6 months | 
| the time at which complications occurs more, during airway management | researchers will observe the whole patients who undergo general anesthesia and record the data | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
airway complications, anesthesia, difficult airway, supraglottic airway device, difficult intubation
Quality of Life in Lymphoma Patients One Year Post-chemotherapy

Study Overview
=================
Brief Summary
-----------------
Malignant lymphomas are considered as among the most chemo-sensitive cancers. ML are cured in more than 85% of patient, the majority with complete response. After this active phase of treatment, patients are in after cancer period. Toulouse University Hospital developed since 2006 the Ambulatory Medical Assistance for After Cancer program on lymphoma patient. Ambulatory Medical Assistance for After Cancer is very efficient for detecting physical and psychological complications which impact quality of life. The investigators identified 22% of lymphoma patients who had a reduced quality of life one year after the end of chemotherapy. The present study aims to investigate the evolution of observed complications and identify cancer care pathway which decrease the quality of life reduction risk in patients one year after lymphoma chemotherapy.

Detailed Description
-----------------
Quality of life, as well anxiety, depression, social isolation, fear of cancer recurrence, post traumatic stress, will be measured in lymphoma patients, after a first line chemotherapy. Care cancer pathway will be also evaluated. Self-administered questionnaires will be performed on website (www.hospitalidee.fr) after inclusion and 12 months after.

Official Title
-----------------
Quality of Life in Lymphoma Patients and Cancer Care Pathway One Year Post-chemotherapy

Conditions
-----------------
Lymphoma

Intervention / Treatment
-----------------
* Other: Quality of life


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients being in complete response after a first therapy for lymphoma Malignant lymphoma (Hodgkin or non-Hodgkin) treated by anthracyclines with a minimum of 6 cycles, followed or not by autologous hematopoietic stem cell transplantation Patients informed of the study and not opposed to the research Exclusion Criteria: Patients under legal guardian . Patients unavailable to formulate non-opposition to the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Lymphoma patients<br>Patients being in complete response after a first therapy for malignant lymphoma. | Other: Quality of life<br>* Quality of life one year post chemo-therapy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quality of life change: Quality of Life-C30 French version | Health-related quality of life is evaluated by the use of Quality of Life-C30 French version | Change from baseline quality of life at 12 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Lymphoma, Quality Of Life, Cancer Care Pathway, Post-Chemotherapy
The Role of FGF23 and Asymmetric Dimethylarginine (ADMA) in Chronic Kidney Disease

Study Overview
=================
Brief Summary
-----------------
In chronic kidney disease calcium (Ca) and phosphate (P) metabolism disorders are very common and also they are one of the leading causes of morbidity in these population. FGF23 is a novel factor that contributes Ca-P disorders. It has been hypothesized that FGF 23 increase is mediated by asymmetric dimethylarginine (ADMA). The aim of the study is to evaluate this hypothesis.

Conditions
-----------------
Metabolic Diseases, Chronic Kidney Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: between ages of 18 - 65 years old chronic kidney disease of stage 2-4 Exclusion Criteria: presence of diabetes mellitus or ischemic hearth disease taking vitamin d therapy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group I<br>Stage 2 Non-diabetic Chronic Kidney Disease | |
| Group II<br>Stage 3 Non-diabetic Chronic Kidney Disease | |
| Group III<br>Stage 4 Non-diabetic Chronic Kidney Disease | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
FGF 23, ADMA, chronic kidney disease, Ca-P metabolism disorder
Frailty in Individuals With Advanced Heart Failure Part 2

Study Overview
=================
Brief Summary
-----------------
To investigate how measures of frailty, assessed during occupational therapy (OT) evaluation and intervention impact decision for advanced heart failure (HF) therapies and postoperative outcomes.

Official Title
-----------------
Frailty in Individuals With Advanced Heart Failure Part 2

Conditions
-----------------
Heart Failure, Frailty

Intervention / Treatment
-----------------
* Procedure: LVAD or Heart Transplant


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Individuals will be included in this study if they were evaluated for advanced heart failure therapies at Keck Hospital from 1/1/2019-6/30/2021. This will be determined through data from the electronic medical record. Exclusion Criteria: Patients who did not receive an occupational therapy evaluation prior to advanced heart failure intervention decision.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Medical Management<br>Patients deemed not candidates for advanced heart failure interventions. | |
| Left Ventricular Assist Device (LVAD)<br>Recipients of a left ventricular assist device | Procedure: LVAD or Heart Transplant<br>* Patients undergoing advanced heart failure intervention including LVAD implantation or heart transplantation<br>|
| Heart Transplant<br>Recipients of a heart transplant. | Procedure: LVAD or Heart Transplant<br>* Patients undergoing advanced heart failure intervention including LVAD implantation or heart transplantation<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hospital Length of Stay | Length of hospital stay after intervention | 1 to 500 days | 
| Rate of Readmission | Rate of Readmission after initial hospital discharge | 30 to 90 days |
Masculine Norms and Skin Care Knowledge, Attitudes, and Behaviors

Study Overview
=================
Brief Summary
-----------------
Examining whether men with greater Avoidance to Femininity subscores using the Male Role Norms Inventory - Short Form will demonstrate differences in skin care knowledge, attitudes, and behaviors, compared to men with lower subscores.

Detailed Description
-----------------
This purpose of this study is to examine whether a man's adherence to traditional masculine norms correlates with his skin care attitudes or behaviors. A stronger understanding of these associations may enable dermatologists to better understand their patient's perception of skin care. The utility of this knowledge lies in creating outreach interventions and informing risk stratification. The study also seeks to determine whether skin care knowledge varies by adherence to masculine norms. This knowledge can be used to guide patient education in a clinical setting.

Official Title
-----------------
Examining the Association Between Adherence to Masculine Norms and Skin Care Knowledge, Attitudes, and Behaviors in Adult Men

Conditions
-----------------
Social Norms

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects age 18 or older Subjects identity as Male Reside in the United States Able to complete an online survey published in English Exclusion Criteria: - Subjects who do not meet the inclusion criteria - Subjects who have previously completed the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 125 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Frequency of skin care behaviors | Research participants will be assigned masculinity classifications based on their Avoidance to femininity subscores. The frequency at which research participants in each masculinity class practice the skin care behaviors assessed in the questionnaire will be reported. The unit of measure will be a numerical value, number of participants. | 2 months | 
| Number of participants with certain skin care attitudes | Research participants will be assigned masculinity classifications based on their Avoidance to femininity subscores. The study will also report the number of participants in each masculinity class with specific skin care attitudes. The unit of measure will be a numerical value, number of participants. | 2 months | 
| Skin Care Knowledge Scores | Research participants will be assigned masculinity classifications based on their Avoidance to femininity subscores. Skin care knowledge scores for each masculinity class will also be reported. The unit of measure will be a numerical value, raw score. | 2 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Masculine Norms, Skin Care, Gender
Sympathetic Transduction in Obesity-associated Hypertension (OB-HTN)

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to understand how the nervous system communicates to blood vessels to increase blood pressure during stress. The study will also investigate how hypertension and obesity influence the nervous system and vascular function. The study will involve measuring sympathetic nervous system activity and blood flow during common laboratory physiological stress protocols (e.g. hypoxia, exercise), and in response to infusion of drugs that cause vasodilation or vasoconstriction.

Official Title
-----------------
Sympathetic Neural Patterns and Transduction in Obesity-associated Hypertension

Conditions
-----------------
Hypertension, Obesity

Intervention / Treatment
-----------------
* Drug: Neuropeptide Y


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Control - BMI<30, age 18-55 Hypertensive - BMI<30, age 18-55, diagnosis of hypertension by 24-hour ambulatory blood pressure monitoring Obese- BMI>30, age 18-55 Obese-hypertensive- BMI>30, age 18-55, diagnosis of hypertension by 24-hour ambulatory blood pressure monitoring Exclusion Criteria: All groups - presence of other significant cardiovascular disease, renal disease, history of smoking, diabetes,

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Healthy Control<br>Healthy age matched controls with no history of cardiovascular disease and normal bodyweight | Drug: Neuropeptide Y<br>* intra-arterial infusion of neuropeptide Y<br>|
| Experimental: Hypertensive<br>Hypertensive adults who are not obese | Drug: Neuropeptide Y<br>* intra-arterial infusion of neuropeptide Y<br>|
| Experimental: Obese<br>Obese adults who are not hypertensive | Drug: Neuropeptide Y<br>* intra-arterial infusion of neuropeptide Y<br>|
| Experimental: Obese-hypertensive<br>Obese adults who are being treated for hypertension | Drug: Neuropeptide Y<br>* intra-arterial infusion of neuropeptide Y<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blood flow measured by doppler ultrasound | brachial and femoral artery blood flow | Acutely on the day of study | 
| Muscle sympathetic nervous system activity | recording of sympathetic nervous system activity from the peroneal or radial nerve | Acutely on the day of study | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
NPY